Literature DB >> 2604386

Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis.

D M Franciotta1, L M Grimaldi, G V Martino, G Piccolo, R Bergamaschi, A Citterio, G V Melzi d'Eril.   

Abstract

We measured levels of alpha-tumor necrosis factor (alpha-TNF) in cerebrospinal fluid and serum samples from 50 drug-free patients with multiple sclerosis, 25 patients with other neurological diseases, 27 patients with non-neurological diseases, and 10 normal subjects. The most elevated levels of alpha-TNF were found in patients with inflammatory or autoimmune diseases. Comparable serum levels of alpha-TNF were detected in normal control subjects, patients with multiple sclerosis, and patients with degenerative neurological diseases. In patients with multiple sclerosis, alpha-TNF levels were also unrelated to time elapsed between the occurrence of clinical exacerbation and the time of sample collection. Only 3 patients with chronic progressive multiple sclerosis had detectable alpha-TNF in the cerebrospinal fluid. Our data do not support a role for elevated levels of circulating alpha-TNF in the maintenance of the disease. However, we cannot rule out the possibility that a transient elevation of alpha-TNF triggers the cellular events leading to demyelination in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2604386     DOI: 10.1002/ana.410260618

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  13 in total

1.  Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.

Authors:  K Selmaj; C S Raine; B Cannella; C F Brosnan
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

2.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

Review 3.  Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis.

Authors:  R W Ledeen; G Chakraborty
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

Review 4.  Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system.

Authors:  K W Selmaj
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 5.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

6.  Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?

Authors:  A Salmaggi; A Dufour; M Eoli; E Corsini; L La Mantia; G Massa; A Nespolo; C Milanese
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

7.  Tumour necrosis factor alpha is elevated in serum and cerebrospinal fluid in multiple sclerosis and inflammatory neuropathies.

Authors:  M Rentzos; C Nikolaou; A Rombos; K Voumvourakis; I Segditsa; C Papageorgiou
Journal:  J Neurol       Date:  1996-02       Impact factor: 4.849

8.  Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

Authors:  C E Shaw; P R Dunbar; H A Macaulay; T J Neale
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

9.  Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.

Authors:  A P Cope; M Londei; N R Chu; S B Cohen; M J Elliott; F M Brennan; R N Maini; M Feldmann
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 10.  Interferons in multiple sclerosis. A review of the evidence.

Authors:  H S Panitch
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.